Transforming Lives

Through a new class of safe, durable cancer treatments.

In The News

    • AUG 03 2017

    Manuscript on ONC201’s Effect on Cancer Stem Cells Published in PLOS ONE

    ONC201 may inhibit cancer stem cell self-renewals by altering their gene expression Pre-treatment gene expression of cancer stem cells may help predict response to ONC201 ONC201 may inhibit cancer stem cell self-renewals by altering their gene expression, according to a study published August 2, 2017 in the open-access journal PLOS ONE by Varun Vijay Prabhu from Oncoceutics,

    • JUL 14 2017

    Musella Foundation Awards Oncoceutics New Research Grant

    The Musella Foundation recently awarded Oncoceutics a $25,000 research grant for a project titled “Clinical Evaluation of DRD5 as a Predictive Biomarker of Response to the selective DRD2 antagonist ONC201.” This will fund Oncoceutics’ work evaluating the impact of dopamine receptor expression on the responsiveness of patient tumors to ONC201, with a focus on glioblastoma